68Ga-PSMA PET/CT对前列腺癌管理意图的影响:澳大利亚前瞻性多中心研究结果
这项澳大利亚前瞻性多中心研究评估了68Ga-PSMA PET/CT对原发或复发前列腺癌患者管理意图的影响。共431例患者完成检查前后管理计划问卷,结果显示51%的患者管理计划发生改变;生化失败组改变比例(62%)高于原发分期组(21%)。68Ga-PSMA PET/CT可发现前列腺床、区域淋巴结和远处转移等先前未怀疑的病变。
要点
- 68Ga-PSMA PET/CT使51%的前列腺癌患者管理计划发生改变。
- 生化失败组管理意图改变比例为62%,高于原发分期组的21%。
- 68Ga-PSMA PET/CT发现前列腺床、区域淋巴结和远处转移的未怀疑病变比例分别为27%、39%和16%。
核心结论
- 68Ga-PSMA PET/CT可检测先前未怀疑的病变,并可能影响大部分前列腺癌患者的计划临床管理。
- 在生化复发患者中影响更大。
- 这些结果展示了68Ga-PSMA PET/CT在前列腺癌管理中的潜在临床价值。
研究设计与样本
- 澳大利亚前瞻性多中心研究,来自4个澳大利亚中心的431例前列腺癌患者完成了68Ga-PSMA PET/CT检查前后的管理计划问卷。
- 25%的患者因中危和高危疾病的原发分期接受扫描,75%的患者因再分期/生化复发接受扫描。
主要发现
- 总体而言,68Ga-PSMA PET/CT导致51%的患者计划管理发生改变。
- 在根治性手术或放疗后生化失败的患者组中管理意图改变比例为62%,高于原发分期患者的21%。
- 68Ga-PSMA PET/CT显示前列腺床未怀疑病变占27%,区域淋巴结占39%,远处转移性疾病占16%。
关键数值与推荐
- 25%的患者扫描用于中危和高危疾病的原发分期,75%用于再分期/生化复发。
- 总体管理改变比例为51%,生化失败组为62%,原发分期组为21%。
- 未怀疑病变检出率:前列腺床27%,区域淋巴结39%,远处转移16%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68Ga-PSMA PET/CT scanning has been shown to be more sensitive than conventional imaging techniques in patients with prostate cancer. This prospective Australian multicenter study assessed whether 68Ga-PSMA PET/CT imaging affects management intent in patients with primary or recurrent prostate cancer. Methods: Before undertaking 68Ga-PSMA PET imaging, referring medical specialists completed a questionnaire detailing relevant demographic and clinical data as well as their proposed management plan. A separate follow-up questionnaire was completed after the 68Ga-PSMA PET/CT scan results were available to determine whether the management plan would change. Results: A total of 431 patients with prostate cancer from 4 Australian centers had pre- and post-68Ga-PSMA management plans completed. Scans were obtained for primary staging of intermediate- and high-risk disease in 25% of patients and for restaging/biochemical recurrence in 75% of patients. Overall, 68Ga-PSMA PET/CT scanning led to a change in planned management in 51% of patients. The impact was greater in the group of patients with biochemical failure after definitive surgery or radiation treatment (62% change in management intent) than in patients undergoing primary staging (21% change). Imaging with 68Ga-PSMA PET/CT revealed unsuspected disease in the prostate bed in 27% of patients, locoregional lymph nodes in 39%, and distant metastatic disease in 16%. Conclusion:68Ga-PSMA PET/CT scans detect previously unsuspected disease and may influence planned clinical management in a high proportion of patients with prostate cancer. The impact was greater in patients with biochemical recurrence. These results demonstrate the potential clinical value of 68Ga-PSMA PET/CT in management of prostate cancer.
引用
- Roach PJ, Francis R, Emmett L, et al. The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. J Nucl Med. 2017. PMID: 28646014. doi:10.2967/jnumed.117.197160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。